葡萄膜炎的药物治疗：当前的管理与新兴疗法。
Pharmacotherapy for uveitis: current management and emerging therapy.
作者信息
Barry Robert J, Nguyen Quan Dong, Lee Richard W, Murray Philip I, Denniston Alastair K
机构信息
Academic Unit of Ophthalmology, Centre for Translational Inflammation, Research, University of Birmingham, UK.
Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA.
出版信息
Clin Ophthalmol. 2014 Sep 22;8:1891-911. doi: 10.2147/OPTH.S47778. eCollection 2014.
Abstract
Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.
摘要
葡萄膜炎是一组以眼内炎症为特征的病症，是劳动人口视力丧失的主要原因。在西方国家，大多数葡萄膜炎是非感染性的，本质上似乎是自身免疫性或自身炎症性的，需要用免疫抑制和/或抗炎药物治疗。在这篇教育综述中，我们概述了治疗葡萄膜炎药物的理想特性，并回顾了支持在这种情况下使用现有和新兴疗法的数据。至关重要的是，我们要继续开发用于葡萄膜炎的新疗法，旨在抑制疾病活动、防止损伤积累，并以尽可能小的副作用为患者保留视觉功能。
相似文献
1
Pharmacotherapy for uveitis: current management and emerging therapy.葡萄膜炎的药物治疗：当前的管理与新兴疗法。
Clin Ophthalmol. 2014 Sep 22;8:1891-911. doi: 10.2147/OPTH.S47778. eCollection 2014.
2
Systemic immunosuppressive therapies for uveitis in developing countries.发展中国家葡萄膜炎的全身免疫抑制疗法。
Indian J Ophthalmol. 2020 Sep;68(9):1852-1862. doi: 10.4103/ijo.IJO_1548_20.
3
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials.葡萄膜炎治疗的最新进展：重点关注部分 2 期和 3 期临床试验。
Expert Opin Emerg Drugs. 2023 Dec;28(4):297-309. doi: 10.1080/14728214.2023.2293049. Epub 2023 Dec 26.
4
Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan.台湾关于使用全身性抗肿瘤坏死因子-α治疗非感染性葡萄膜炎的建议。
Taiwan J Ophthalmol. 2018 Jul-Sep;8(3):117-120. doi: 10.4103/tjo.tjo_32_18.
5
Side-effects of anti-inflammatory therapy in uveitis.葡萄膜炎抗炎治疗的副作用。
Semin Ophthalmol. 2014 Sep-Nov;29(5-6):456-67. doi: 10.3109/08820538.2014.959203.
6
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.人源化抗Tac单克隆抗体治疗非感染性中间葡萄膜炎和后葡萄膜炎：一项I/II期临床试验。
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7462-6. doi: 10.1073/pnas.96.13.7462.
7
Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.自身免疫性葡萄膜炎：临床、发病机制及治疗特点
Clin Exp Med. 2016 May;16(2):125-36. doi: 10.1007/s10238-015-0345-6. Epub 2015 Mar 28.
8
Intravitreal injection therapy in the treatment of noninfectious uveitis.玻璃体内注射疗法治疗非感染性葡萄膜炎。
Dev Ophthalmol. 2012;51:110-21. doi: 10.1159/000336471. Epub 2012 Apr 17.
9
New pharmacotherapy options for noninfectious posterior uveitis.非感染性后葡萄膜炎的新药物治疗选择
Expert Opin Biol Ther. 2014 Dec;14(12):1783-99. doi: 10.1517/14712598.2014.956074. Epub 2014 Sep 22.
10
A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I.成人非感染性葡萄膜炎非生物治疗的全面综述与更新：第一部分。
Expert Opin Pharmacother. 2014 Oct;15(15):2141-54. doi: 10.1517/14656566.2014.948417.
引用本文的文献
1
Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases.皮下注射长效促肾上腺皮质激素治疗难治性眼部炎性疾病的疗效及耐受性
J Ophthalmic Inflamm Infect. 2024 Oct 24;14(1):56. doi: 10.1186/s12348-024-00428-8.
2
Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.非感染性葡萄膜炎治疗的最新进展：抗肿瘤坏死因子-α及其他疗法
Front Ophthalmol (Lausanne). 2024 Aug 2;4:1412930. doi: 10.3389/fopht.2024.1412930. eCollection 2024.
3
Healthcare professionals' views on the most important outcomes for non-infectious uveitis of the posterior segment: A qualitative study.医疗专业人员对后段非感染性葡萄膜炎最重要结局的看法：一项定性研究。
PLoS One. 2023 Nov 17;18(11):e0294117. doi: 10.1371/journal.pone.0294117. eCollection 2023.
4
Effects of Subcutaneous Methotrexate in Patients with Refractory Uveitis and Chorioretinitis.皮下注射甲氨蝶呤治疗难治性葡萄膜炎和脉络膜炎的疗效。
Korean J Ophthalmol. 2023 Dec;37(6):446-452. doi: 10.3341/kjo.2023.0073. Epub 2023 Oct 25.
5
Extracellular vesicles as a new horizon in the diagnosis and treatment of inflammatory eye diseases: A narrative review of the literature.细胞外囊泡作为炎症性眼病诊治的新领域：文献综述。
Front Immunol. 2023 Mar 9;14:1097456. doi: 10.3389/fimmu.2023.1097456. eCollection 2023.
6
Comprehensive LncRNA and Potential Molecular Mechanism Analysis in Noninfectious Uveitis.非感染性葡萄膜炎中的综合长链非编码 RNA 与潜在分子机制分析。
Transl Vis Sci Technol. 2023 Mar 1;12(3):2. doi: 10.1167/tvst.12.3.2.
7
Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives.用于非感染性葡萄膜炎的局部抗炎药：当前治疗方法与展望
J Inflamm Res. 2022 Nov 28;15:6439-6451. doi: 10.2147/JIR.S288294. eCollection 2022.
8
Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: a survey study.非感染性葡萄膜炎局部糖皮质激素治疗的实践模式：一项调查研究。
J Ophthalmic Inflamm Infect. 2022 Jan 4;12(1):3. doi: 10.1186/s12348-021-00281-z.
9
Annexin A1 Mimetic Peptide and Piperlongumine: Anti-Inflammatory Profiles in Endotoxin-Induced Uveitis.膜联蛋白A1模拟肽与胡椒碱：内毒素诱导性葡萄膜炎中的抗炎作用
Cells. 2021 Nov 15;10(11):3170. doi: 10.3390/cells10113170.
10
A Non-Infectious Uveitis Multidisciplinary Clinic in a Tertiary Referral Center: Clinical Impact and Added Value.三级转诊中心的非感染性葡萄膜炎多学科诊所：临床影响与附加价值
J Multidiscip Healthc. 2021 Mar 22;14:695-704. doi: 10.2147/JMDH.S292981. eCollection 2021.
本文引用的文献
1
Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.全身生物制剂在非感染性葡萄膜炎治疗中的应用进展
Biologics. 2014 Feb 15;8:67-81. doi: 10.2147/BTT.S41477. eCollection 2014.
2
Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis.一名类风湿关节炎患者停用托珠单抗后发生急性前葡萄膜炎。
Clin Ophthalmol. 2014 Jan 8;8:187-90. doi: 10.2147/OPTH.S54929. eCollection 2014.
3
Interleukin-6 blockade in ocular inflammatory diseases.白介素 6 阻断在眼部炎症性疾病中的应用。
Clin Exp Immunol. 2014 Jun;176(3):301-9. doi: 10.1111/cei.12295.
4
Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient.托珠单抗用于一名儿科患者中与幼年特发性关节炎相关的重度慢性前葡萄膜炎。
Ocul Immunol Inflamm. 2014 Apr;22(2):155-7. doi: 10.3109/09273948.2013.866254. Epub 2013 Dec 30.
5
New options for uveitis treatment.葡萄膜炎治疗的新选择。
Int J Ophthalmol. 2013 Oct 18;6(5):702-7. doi: 10.3980/j.issn.2222-3959.2013.05.29.
6
Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties.详细的机制分析 gevokizumab，一种具有差异化受体调节特性的变构抗 IL-1β 抗体。
J Pharmacol Exp Ther. 2014 Jan;348(1):202-15. doi: 10.1124/jpet.113.205443. Epub 2013 Nov 5.
7
The future of uveitis treatment.葡萄膜炎治疗的未来。
Ophthalmology. 2014 Jan;121(1):365-376. doi: 10.1016/j.ophtha.2013.08.029. Epub 2013 Oct 26.
8
Long-term treatment with golimumab for severe uveitis.使用戈利木单抗长期治疗严重葡萄膜炎。
Ocul Immunol Inflamm. 2014 Apr;22(2):90-5. doi: 10.3109/09273948.2013.844265. Epub 2013 Oct 21.
9
Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series.戈利木单抗治疗血清阴性脊柱关节病相关性葡萄膜炎：回顾性病例系列
Clin Exp Ophthalmol. 2014 May-Jun;42(4):392-5. doi: 10.1111/ceo.12207. Epub 2013 Oct 23.
10
Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.抗 TNF 治疗在三种常见疾病中的超适应证应用：白塞病、结节病和非感染性葡萄膜炎。
Mediators Inflamm. 2013;2013:286857. doi: 10.1155/2013/286857. Epub 2013 Aug 1.
Zotero 插件